Phase 3 N=939 Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)
Infertility
Primary: Number of Oocytes Retrieved — 3.3; 3.6 oocytes — p=0.054
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,111 An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Rheumatoid Arthritis
Primary: Least Squares Mean Change From Baseline in Disease Activity Score (3 Variables)-Erythrocyte Sedimentation Rate at Month 6 — -1.5; -1.1 scores on a scale — p=0.0068
N/A N=16 Feasibility Study Evaluating the ParaPatch System
Urinary Incontinence
Primary: Number of Participants Who Used the ParaPatch System With Adverse Events Through the Completion of the Study — 8; 6 participants
Phase 3 N=56 Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Renal Function · Liver Transplant
Primary: Change From Baseline in Estimated Glomerular Filtration Rate - Month 12 — 6.2 mL/min/1.73m^2
N/A N=295 Vistakon Investigational Multi-purpose Contact Lens Care Solution.
Contact Lens Wear
Primary: Slit Lamp Findings (SLF) — 0; 0; 0; 0 eyes (2 per subject)
N/A N=5,025 A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Crohn's Disease
Primary: Number of Participants With Registry Treatment-Emergent Adverse Events (AEs) — 2392; 1853; 596; 43 Participants
Phase 4 N=532 Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — -1.61; -1.58 Percentage of HbA1c
Phase 2 N=395 A Study of Medication With or Without Psychotherapy for Complicated Grief
Complicated Grief · Bereavement
Primary: Responder Status Based on Complicated Grief Clinical Global Impression-Improvement (CGI-I) Scale — 46; 38; 84; 83 percentage of responders — p=<0.05
N/A N=30 Continuous Glucose Monitor in Children With Poorly Controlled Diabetes
Type 1 Diabetes Mellitus
Primary: The Primary Outcome Measure Was Change in HgbA1c — -0.95; -0.9; -0.6; -0.9 HbgA1c % — p=< 0.05
Phase 2 N=47 Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Confirmed Response Rate — 0.67 proportion of patients
Phase 3 N=420 Lamotrigine Phase III Study in Bipolar I Disorder
Bipolar Disorder
Primary: Time to Intervention for Any Mood Episode (TIME) — NA; NA Days — p==0.438
Phase 2 N=884 A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Pneumococcal Infection
Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events — 148; 153; 187; 213 participants
Phase 3 N=311 Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393
Phase 2 N=42 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response — 11.8 percentage
Phase 3 N=242 Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
Open Angle Glaucoma · Ocular Hypertension
Primary: Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye — -0.51; -0.52 mm Hg